Article

Harvoni Shows Success Against Uncommon HCV Variants

A treatment approved for the most common form of hepatitis C in the US was also highly effective in less widespread variants, researchers reported at the European Association for the Study of the Liver annual meeting.

A treatment approved for the most common form of hepatitis C (HCV) in the US was also highly effective in less widespread variants, researchers reported.

The 2-drug single-pill combination of sofosbuvir and ledipasvir (Harvoni) is indicated in the U.S. for genotype 1 HCV infection, noted Armand Abergel, MD, PhD, of the Hopital d'Estaing in Clermont-Ferrand, France, and colleagues.

But in an open-label study among patients with genotypes 4 and 5 disease, the combination yielded efficacy results that were similar to those seen in genotype 1, Dr Abergel reported in a plenary session at the European Association for the Study of the Liver annual meeting.

Read more at MedPage Today: http://bit.ly/1b6xuWA

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Hans Lee
Dr María Díez Campelo
4 experts in this video
4 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo